AGIO

Agios Pharmaceuticals, Inc.

A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.